The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
|Videos|December 31, 2019
Experts Provide Insight on the Biggest Advances in Oncology in 2019
Author(s)OncLive Staff
OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.
Advertisement
OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5